All Updates

All Updates

icon
Filter
Partnerships
Foundation Medicine partners with Repare Therapeutics to support oncology clinical trials and diagnostics development
Precision Medicine
Jun 12, 2024
Last week:
M&A
Nscale acquires Kontena to enhance HPC and AI infrastructure capabilities
Generative AI Infrastructure
Yesterday
Product updates
Eve Air Mobility unveils unmanned eVTOL prototype
Passenger eVTOL Aircraft
Yesterday
Product updates
Lilium advances POWER-ON, providing solutions with leading digital innovators
Passenger eVTOL Aircraft
Yesterday
Product updates
Together AI unveils new inference stack and endpoints for improved speed and efficiency
Generative AI Infrastructure
Jul 20, 2024
Industry news
New South Korean space agency provides rundown of plans
Space Travel and Exploration Tech
Jul 20, 2024
Product updates
Micron Technology introduces high-performance MRDIMMs to improve bandwidth for AI and HPC applications
Generative AI Infrastructure
Jul 19, 2024
Management news
Bionano Genomics receives Nasdaq non-compliance notice; continues trading efforts
Precision Medicine
Jul 19, 2024
Funding
GRO Biosciences raises USD 60.3 million in Series B funding to advance lead program into clinical trials and expand GRObio pipeline
Precision Medicine
Jul 19, 2024
Management news
Yooz announces new appointments in C-Suite
Business Expense Management
Jul 19, 2024
Regulation/policy
Airwallex secures license to expand retail investment offerings in Australia
FinTech Infrastructure
Jul 19, 2024
Precision Medicine

Precision Medicine

Jun 12, 2024

Foundation Medicine partners with Repare Therapeutics to support oncology clinical trials and diagnostics development

Partnerships

  • Foundation Medicine has partnered with Repare Therapeutics to offer genomic profiling for patients participating in Repare's ongoing MYTHIC study involving the Lunresertib drug.

  • The collaboration aims to use FoundationOneCDx, a comprehensive genomic profiling test, as a potential companion diagnostic for the Lunresertib program. Lunresertib is currently being assessed individually and in combination in several studies across Europe and North America. The partnership seeks to use and advance diagnostics in cancer treatment, especially in cases with complex biomarkers and high unmet needs. 

  • Foundation Medicine specializes in comprehensive genomic profiling for cancer treatment. The company provides clinical diagnostic tests that analyze cancer’s genetic alterations, enabling personalized treatment plans. Its key products include FoundationOneCDx, FoundationOneLiquid CDx for blood-based cancers, and FoundationOneHeme for hematologic malignancies. ​

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.